A Prospective, Randomized, Comparative Effectiveness Trial of the ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations
| City: |
|
Washington |
| State: |
|
District of Columbia |
| Zip Code: |
|
20007 |
| Conditions: |
|
Chronic Venous Hypertension With Ulcer |
| Purpose: |
|
This is a prospective, randomized, comparative interventional human subject trial. Patients
with a chronic venous ulceration of the lower extremity will be enrolled into this study.
These wounds must be recalcitrant to the standard treatment regimen. There are a total of
two arms in this study. One group will be randomly assigned to the Acti VAC + Compression
therapy group consisting of the application of this device along with compression therapy.
The other group will be randomly assigned into compression therapy only group. A total of
60 subjects will be enrolled into this 6 week study. There will be a 2 week run-in period
(prior to the onset of the intervention) to ensure that the wound has not healed greater
than 35% prior to intervention and randomization. Wounds that heal within the 6 week trial
period will have an additional confirmatory visit 2 weeks after healing was identified.
If within the 6 week intervention period the wound bed is determined to be ready for a Split
Thickness Skin Graft (STSG) or Bio-engineered Alternative Tissue (BAT), the surgery or
clinic application will be scheduled within 4 weeks. Subjects deemed not to be a surgical
candidate, will have Bio-engineered Alternative Tissue (BAT) application in the clinic.
This includes patients who are medically unstable to receive a medical clearance for surgery
or otherwise not a candidate for Split Thickness Skin Graft (STSG) surgery (e.g. donor site
skin is compromised). During this period between the scheduled STSG surgery or BAT
application, the subjects will continue within the assigned treatment group. A confirmatory
visit will also occur 2 weeks after the application of a Split Thickness Skin Graft (STSG)
or Bio-engineered Alternative Tissue (BAT).
Patients diagnosed with a chronic venous ulceration will be assessed for study eligibility
during their initial clinical evaluation. Patients who meet the eligibility requirements
will be asked to enroll into the study (see Subject Recruitment). Subjects will be asked to
sign the informed consent form and receive a copy of the informed consent.
|
| Study Summary: |
|
Patients diagnosed with a chronic venous ulceration will be assessed for study eligibility
during their initial clinical evaluation. Patients who meet the eligibility requirements
will be asked to enroll into the study (see Subject Recruitment). Subjects will be asked to
sign the informed consent form and receive a copy of the informed consent. The study will
be conducted in the following manner:
Prescreening, Screening, and Enrollment
- Obtain informed consent
- Assess patients for eligibility based on inclusion/exclusion criteria
- Initial quality of life questionnaire completed
- Target ulcer
• If more than 1 wound is present on either leg; the target ulcer will be the one that
is the largest in overall dimensions. All other ulcers will be treated per Standard of
Care.
- Photo/wound measurements
- Venous studies (if necessary to confirm diagnosis)
- Case Record Form (CRF) completed
- Subjects will continue with Standard of Care until treatment initiation visit
- If a patient is currently undergoing pump or pneumatic compression therapy, they
must discontinue this treatment at least 2 week before the treatment initiation
visit
Treatment Initiation Visit and Randomization
- Begin 2 weeks after the above enrollment visit - Confirm continued eligibility:
- Photo/wound measurements (to be performed before and after debridement)
- Exclude if wound size has decreased > 35% - Randomization into the 2 treatment
groups
1. ActiV.A.C. System Negative Pressure Therapy + Compression Therapy
2. Compression Therapy - Quality of life questionnaires completed
- CRF completed Subjects will have 1 visit in the clinic and 1 visit by a
home nurse to change the dressing and Acti V.A.C ( if applicable) weekly
Weekly Follow-Up
- Visits must be ± 2 days of scheduled appointment
- Photo/wound measurements (to be performed before and after debridement)
- Change ActiV.A.C. System+ Compression Therapy or Compression Therapy
- Quality of life questionnaires to be completed at weeks 4, 6
- CRF completed
- If the subject is has not healed or healed, and the wound is not ready for a Split
Thickness Skin Graft (STSG) or Bio-engineered Alternative Tissue (BAT)at the 6
week time point, then the patient will be exited from the study (see Close-Out)
- If the subject has not healed within the 6 week interventional phase, but the
wound is ready for a Split Thickness Skin Graft or Bio-engineered Alternative
Tissue (BAT), they will be scheduled for a Split Thickness Skin Graft (STSG) or
Bio-engineered Alternative Tissue (BAT)
Close-Out
- If the subject has not healed, they will be exited from the study at the 6 week time
point
- Photo/wound measurements (to be performed before and after debridement)
- Close-out specific CRF completed
- Complete quality of life questionnaires
- Follow-up treatment plan with individual investigator
Confirmatory Visit
- If the target wound has healed within the 6 week interventional period, the subject
will be scheduled for this confirmatory visit 2 weeks after wound has been deemed to be
healed
- Photo/wound measurements (to be performed before and after debridement)
- Close-out specific CRF completed
- Complete quality of life questionnaires
- Follow-up treatment plan with individual investigator
Split Thickness Skin Graft (STSG) or Bio-engineered Alternative Tissue (BAT)- If the wound
is deemed ready for Split Thickness Skin Graft (STSG) or Bio-engineered Alternative Tissue
(BAT) then the subject will either:
- Be scheduled for surgery for application of a Split Thickness Skin Graft within 4 weeks
- Have Bio-engineered Alternative Tissue (BAT)applied in the clinic within 4 weeks
- Subject will continue with their intervention until the date of surgery
- After Split Thickness Skin Graft, subjects will receive SOC utilizing the
ActiV.A.C. ™ + Compression Therapy
- After Bio-engineered Alternative Tissue (BAT), subjects will receive Standard of
Care utilizing compression therapy
- Photo/Wound Measurements (to be performed before and after debridement)
- CRF completed
- Subjects will have a f/u visit within 5-7 days for dressing change per Standard of
Care
Close-Out/Confirmatory Visit for Split Thickness Skin Graft (STSG) or Bio-engineered
Alternative Tissue (BAT)
*2 weeks from the date of surgery (Split Thickness Skin Graft) or clinic application
(Bio-engineered Alternative Tissue)
- Regardless if the target wound is healed or not, the subject will be exited from the
study
- Photo/Wound measurements
- Percent adherence for subjects who received a Split Thickness Skin Graft
- Close-out specific CRF completed
- Complete quality of life questionnaires
- Follow-up treatment plan with individual investigator
Application of Devices/Dressing
The usual consent forms that are part of the Standard of Care will be utilized per the
Center for Wound Healing at Georgetown University Hospital. All costs associated with the
clinic visit consistent with the Standard of Care will be billed in the customary fashion.
Standard of Care Wound Therapy (Debridement, Infection Control)
The surface of the venous wound will be washed and rinsed with a wound cleanser at every
visit per Standard of Care. The need for debridement (utilizing a scalpel and/or curette)
will be dependent of the amount of nonviable tissue and/or biofilm detected on the surface
of the wound. The decision to debride will be made by the individual investigator at each
visit. The use of topical enzymatic debriding agents will be at the discretion of the
investigator. Further, the investigator may use topical antimicrobials as needed. The use
of oral antibiotics will also be at the discretion of the individual investigator. No other
wound healing modalities including topically applied treatments will be allowed.
ActiV.A.C.® Therapy System
The ActiV.A.C.® Therapy System is an FDA approved device for the treatment of venous
ulcerations. The ActiV.A.C.® System will be applied in a customary manner per
manufacturer's recommendations. Acticoat Flex 7™ will be applied as the contact layer on
the wound surface. Acticoat Flex 7™ is a fenestrated, silver-coated (anti-microbial),
knitted polyester material that is routinely used as a contact layer dressing for chronic
wounds. The open cell foam is then applied over the top of the Acticoat Flex 7™ (cut to
shape of the wound). The adherent transparent occlusive material will be applied over the
open cell foam. The tubing is then attached after cutting a small aperture through the
occlusive material. Negative pressure will be set at 125mmHg on continuous suction. The
sponge and canister will be replaced 2 times per week. This dressing change will take place
once in the clinic and once by the visiting home nurses. These nurses have had in-service
training on the proper application of negative pressure therapy and have experience with its
use.
Compression Therapy
Profore™ multi-layered compression bandaging system will be utilized. This includes the
application of a contact layer dressing using Acticoat Flex 7™. The compression bandage
will be applied per manufacturer's recommendations. The dressings will be changed 2 times
per week. This dressing change will take place once in the clinic and once by the visiting
home nurses. These nurses have had in-service training on the proper application of the
compressive dressing and have experience with its use.
Standard of Care Post Split-Thickness Skin Graft or Application of a Bio-engineered
Alternative Tissue (BAT)-
The application of a Split Thickness Skin Graft (STSG) or Bio-engineered Alternative Tissue
(BAT) will follow the Standard of Care. This Standard of Care applies to both
interventional groups. Split Thickness Skin Grafts will be applied in the operating room
after debridement of the venous wound which will be conducted per Standard Of Care. After
the placement of the Split Thickness Skin Graft onto the wound surface, a nonadherent
dressing is placed onto the graft followed by a silver impregnated dressing layer. The
ActiV.A.C.™ open celled foam will then be placed over the silver impregnated dressing in the
customary fashion. Compressive dressing will then be placed over the ActiV.A.C.™ occlusive
material. The postoperative dressings will be removed within 5-7 days. The wound site will
then be redressed with a nonadherent dressing as the contact layer, silver impregnated
dressing, and Profore™. The application of a BAT will take place in the outpatient clinic.
This includes the debridement of the wound and the application of a Bio-engineered
Alternative Tissue (BAT) onto the wound surface. The dressings include a nonadherent
contact layer, followed by a silver impregnated dressing, and finally a Profore™ compressive
dressing.
|
| Criteria: |
|
Inclusion Criteria:
1. Subjects between 18-75 years of age
2. Subject able and willing to comply with study protocol requirements and able to
understand the informed consent
3. Non-pregnant female willing to take urine pregnancy test
4. Chronic venous ulceration of the lower extremity
- Defined: wound of greater than 1 month in duration
- Diagnosis based on clinical assessment and/or venous studies
- <100 cm2 area and <10cm at the widest diameter
Exclusion Criteria:
1. Active infection (redness, swelling, pain, purulence)
2. Untreated osteomyelitis or current osteomyelitis
3. Allergy or sensitivity to wound study products
4. Malignancy
5. Plantar surface wounds
6. BMI (Body Mass Index) ≥50
7. Uncontrolled diabetes (HbA1c>12%) at the time of study screening
8. End stage renal disease
9. Undergoing chemotherapy/radiation therapy
10. Non-dopplerable pedal pulses or otherwise diagnosed with peripheral arterial disease
or any contraindication to compression therapy
11. Any previous wound care therapy including negative pressure therapy, ultrasound
therapy, BAT, or STSG within the previous 30 days of enrollment; this excludes
compression therapy
12. Greater than 35% wound surface area reduction in size at 2 weeks after initial
screening visit
13. Pregnancy
14. Subject has any condition that, in the opinion of the investigator, makes the subject
inappropriate to take part in this study
15. Subject unwilling or unable to comply with protocol requirements
|
| NCT ID: |
|
NCT01528293 |
| Primary Contact: |
|
Principal Investigator
Christopher Attinger, M.D
Georgetown University Hospital
Paul Kim, DPM
Phone: 202-444-0469
Email: Paul.J.Kim@gunet.georgetown.edu
|
| Backup Contact: |
|
Email: Mallory.W.Nichols@gunet.georgetown.edu
Mallory W Nichols, B.S
Phone: 202-444-0283
|
| Location Contact: |
|
Washington, District of Columbia 20007
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|